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Abstract
Background: In animal models, excess luminal iron exacerbates colonic inflammation and cancer development.
Moreover, in inflammatory bowel disease (IBD) patients with mild to moderate disease activity dietary fortificant
iron intake is inversely related to quality of life. Here we sought to determine whether dietary iron intakes were also
related to quality of life in IBD patients in remission.
Methods: Forty eight patients with ulcerative colitis (UC), 42 of which had quiescent disease during this
observational study, and 53 healthy control subjects completed quality of life questionnaires and 7-day food diaries.
For comparative analysis, 34/group were matched and the linear relationship between dietary iron intakes (total,
haem, non-haem or fortificant) and EuroQol quality of life measures was investigated. For UC patients the linear
relationship between dietary iron intakes and the scores from the disease specific inflammatory bowel disease
questionnaire (IBDQ) was also considered.
Results: The intake of dietary iron, and its various sub-fractions, were not associated with quality of life (EuroQol) in
patients with quiescent disease or in healthy control subjects. The picture was similar for the 42 quiescent UC
patients when disease-specific IBDQ was used. However, the 6 patients who relapsed during the study again
showed an inverse association between IBDQ and dietary iron intake (p = 0.03).
Conclusions: Our data suggest that dietary iron does not impact on quality of life in quiescent UC patients but
support that, once the disease is triggered, luminal iron may be a permissive factor for exacerbation of disease
activity resulting in lower quality of life.
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Background
Anaemia due to iron deficiency is prevalent amongst
patients with inflammatory bowel disease (IBD) [1-3].
Although prescription of oral iron therapy is common
practice it may, on occasions, undermine the intended
benefits of therapy by simultaneously aggravating symp-
toms and thereby possibly reducing quality of life in these
patients [4]. For patients who are not in stable remission,
aggravation of gastrointestinal symptoms could occur
through the overproduction of harmful reactive oxygen
species in the colon, catalysed by a surplus of unabsorbed
supplemental iron [5]. Indeed, in murine models of
IBD, high levels of dietary iron increase inflammation
and colonic lipid peroxidation, and induce mucosal damage
[6,7]. Furthermore, IBD patients have an increased risk
of developing colorectal cancer [8] and, worryingly, recent
murine studies have suggested strong promotion of
intestinal tumorigenesis with an increase in luminal iron
concentration [9,10].
Reactive (or ‘free’) iron in the intestinal lumen has not
been characterised. However, even for supplementation
with soluble ferrous (Fe(II)) iron salts most of the iron
will not remain in the lumen in a readily reactive form.
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Oxidation, and then oxo-hydroxide precipitation, in the
gut lumen will greatly limit the ‘free’ iron. Thus free
reactive iron in the gut lumen, that can exacerbate
inflammation, may occur at only a low concentration.
In light of this, the potential adverse effects of iron at
normal (or near normal) fortified dietary iron intake
levels have been investigated albeit data are still scarce.
Nonetheless, all suggest a potential detrimental effect of
iron. An intervention study in healthy, non-anaemic
middle-age men using flour fortified with 30 mg Fe/kg
as ferrous sulphate for more than 1 year has shown a
significant increase in systemic biomarkers of oxidative
stress such as superoxide dismutase and glutathione
peroxidase [11]. Zimmermann et al. have reported signifi-
cant changes towards a more detrimental gut microflora
profile in children supplemented with electrolytic iron-
fortified biscuits for 6 months [12]. To our knowledge, the
only human study in IBD is our own recently published
data indicating a detrimental effect of dietary iron, in
particular from Fe-fortified products, on the quality of
life of IBD patients with mild-moderately active disease
[13]. The aim of the observational study presented
herein was to determine the effect of dietary iron intakes
on the quality of life of ulcerative colitis (UC) patients
with inactive (i.e. quiescent) disease for at least 1 month.
In particular, and unlike in our previous work, we used
a single, defined and larger (n = 50) IBD population
(quiescent UC) and used the most robust, albeit resource-
consuming, dietary assessment technique, namely 7-day
food diaries. As a reference group we also studied healthy




This observational study was conducted according to the
guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved
by the Cambridge Central Research Ethics Committee
(11/EE/0312). Written informed consent was obtained from
all subjects.
Fifty ulcerative colitis (UC) patients were recruited from
gastrointestinal outpatient clinics at Lister Hospital
(Stevenage), Addenbrooke’s Hospital (Cambridge) and
Queen Elizabeth II (QE2) Hospital (Welwyn Garden City),
all in the United Kingdom. Fifty healthy control sub-
jects were recruited from the general population in the
Cambridgeshire area. Controls were matched with cases
for gender and age (within 5 years).
All participants completed a 7-day, estimated food diary
and a EuroQol EQ-5D-5 L health-related quality of life
questionnaire. In addition, patients with ulcerative colitis
completed a disease specific quality of life questionnaire,
namely the Inflammatory Bowel Disease Questionnaire
(IBDQ), as well as a disease activity form, i.e. the Simple
Clinical Colitis Activity Index (SCCAI).
Patients
Eligible case patients included those aged 18 – 80 with a
confirmed diagnosis of ulcerative colitis by histological
and/or radiological techniques and with disease in remis-
sion at the time of enrolment in the trial (minimum of
3 months). Clinical remission was defined as SCCAI < 5
[14]. Exclusion criteria were active UC (i.e. SCCAI ≥ 5),
anaemia of any kind (haemoglobin < 12 g/dL), other
chronic disease, any form of iron therapy, proton-pump
inhibitor therapy, eating disorders, pregnancy or breast-
feeding. Patients who had received over-the-counter iron
supplementation, erythropoiesis stimulating agents (EPO)
or blood transfusions in the previous 28 days were also
excluded.
Controls
The control group was recruited from the general popula-
tion and consisted of healthy subjects aged 18–80 years old
with no history of chronic disease, gastrointestinal disease
or anaemia. Further exclusion criteria were as above.
Quality of life questionnaires
The EuroQol EQ-5D-5 L is self-administered and is
comprised of five dimensions of health: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression
[15,16]. Each dimension has five levels: (1) no problems,
(2) slight problems, (3) moderate problems, (4) severe
problems, (5) inability/extreme problems. An ‘index value’
from 0–1 is generated using the Crosswalk Index Value
Calculator [17,18]. In addition, the questionnaire captures
a self-rating of health status by a visual analogue scale
(VAS) which is limited at 100 (best imaginable health) and
0 (worst imaginable health).
The McMaster IBDQ is specific to inflammatory bowel
disease and has been extensively validated [19-21]. This
questionnaire is more sensitive to changes in quality of life
for patients with inflammatory bowel disease compared
to general health questionnaires, and is able to display
changes in disease activity for patients with ulcerative
colitis or Crohn’s disease [22]. The McMaster IBDQ
consists of 32 questions designed to assess four different
domains: emotional, bowel, social and systemic. Each
question is scored on a seven point Likert scale (1, worst
function; 7, best function) and the final score ranges
from 32 to 224. Higher scores indicate a better quality of
life. The questionnaire was self-administered.
Disease activity
The Simple Clinical Colitis Activity Index (SCCAI) was
used to determine whether patients remained in disease
remission following referral by their gastrointestinal
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consultant and to provide a formal IBD disease activity
score upon enrolment in the study [23]. The SCCAI
consists of 4 questions regarding bowel movements, one
question regarding general wellbeing and an area to report
any extra-colonic features (one point per manifestation).
A score of 5 or more indicates disease relapse [14].
Dietary assessment
All subjects completed a 7-day estimated diet diary which
has been validated with data from the European Prospect-
ive Investigation into Cancer (EPIC) [24]. Subjects were
asked to record everything they had to eat or drink and to
use household measurements to describe portion size.
Subjects also collected all food packaging to increase
the accuracy of the dietary data entry. Data from the diet
diaries were recorded using in-house programme DINO
(Diet In Nutrients Out) which is an all-in-one dietary
recording and analysis system written in Microsoft Access
[25]. DINO was developed at MRC Human Nutrition
Research and incorporates the Department of Health’s
Nutrient Databank [26] and McCance and Widdowson’s
Composition of Foods series [27]. Quality was assured
by a random 10% check of all entered diaries. After data
entry, each participant’s mean energy and nutrient intake
over the seven diary days were calculated.
Additionally, as before [13] fortificant iron intakes were
calculated separately as detailed below and comprised
foods that are fortified with iron on a voluntary basis by
manufacturers (e.g. breakfast cereals), as well as foods
containing white flour (e.g. bread), which is restored
with iron by law. Fortificant iron was calculated as follows:
(i) for food products which are fortified with iron to varying
levels at the discretion of the manufacturer, e.g. breakfast
cereals, the level of ‘natural’ (i.e. not added) non-haem iron
was estimated based on the ingredient information using
the McCance and Widdowson food composition tables
[27], and this value was then subtracted from the total
iron content declared by the manufacturer to estimate
fortificant iron content; and (ii) for other foods containing
white wheat flour, which is fortified with iron as a require-
ment under the UK Bread and Flour Regulation 1995,
fortificant iron was estimated by considering the content
of white flour per food portion and using the standard
‘restoration’ formula of 1.65 mg Fe/100 g white flour to
derive the content of fortificant iron per food portion.
All values for the different categories of dietary iron were
calculated as total daily intakes for each subject.
Statistical analysis
A sample size of 50 subjects per group was calculated to
give 88% power to detect a 2 point decrease in the disease
specific quality of life score for each 1 mg increase in iron
intake. This sample calculation was based on our previous
data [13] demonstrating a similar effect size in a linear
Figure 1 Study participants flow chart. From the 236 initially responding subjects 133 decided not to take part when they received more
detail of study. The 2 patients that did not complete the study did so for reasons unrelated to the study.
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regression analysis with residual standard error of 26 for
the quality of life score and standard deviation for iron
intake of 5.25.
Unless otherwise stated, all statistical analysis was
performed using GraphPad Prism 6 for Windows (Graph-
Pad Software, San Diego, California, USA). Normality of
the data was tested with the D’Agostino and Pearson
omnibus normality test. Comparisons between case pa-
tients and controls in terms of diet and quality of life were
made using the Mann–Whitney nonparametric test.
Results are presented as means with standard deviations
(SD). Significance of associations between the intakes of
the different fractions of dietary iron and quality of life
were assessed using simple linear regression analysis
(Gaussian distribution of X-data not assumed) and multiple
linear regression (with SPSS Statistics 21). Comparison of
the slopes for the respective associations of quality of life
and dietary iron intakes, between UC patients with disease
in remission and those with disease in relapse, were
performed by analysis of covariance (ANCOVA). Statistical
significance was assumed at p < 0.05.
Results
A total of 103 subjects were enrolled in the study (Figure 1).
Of the UC cases that completed the study 26 were male
(54%) and 22 were female (46%) with a mean age (range)
of 50 (23–78) years. Of the healthy controls 26 were male
(49%) and 27 were female (51%) with a mean age (range)
of 41 (20–76) years. The differences between groups were
not statistically significant. Six UC patients relapsed during
the study and were, therefore, excluded from the main
analysis. Of the remaining UC patients 34 were matched
for age (within 5 years) and gender with controls.
The mean EuroQol VAS score for the UC patients
with quiescent disease (i.e. in remission) was 81% (95%
CI = 76–85), which was significantly lower than that
of matched controls (87%: 95% CI = 84–91) (p = 0.007).
Dietary intake of all ‘forms’ of iron (i.e. total, haem,
Figure 2 Association between dietary iron intakes and quality of life measured with EuroQol VAS (EQ VAS%) in UC patients with
quiescent disease (closed triangles and full black line) and matched ‘healthy’ controls (open circles and dashed black line). A, total
dietary iron; B, haem iron; C, non-haem iron; D, fortificant iron. There were no significant slope deviations from zero (linear regression) for both
UC patients and matched controls (p > 0.05, n = 34 per group).
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non-haem and fortificant) had no statistical significant
linear association with the EuroQol VAS score in the
matched cases and controls (Figure 2). Similarly when
the unmatched datasets were compared in their entirety
(i.e. 42 UC patients in remission and 53 controls) there
was again no difference between the two groups and no
association with dietary iron intakes. The same was true
when using the EuroQol index value (Additional file 1:
Figure S1) or the IBDQ score (patients only) as quality
of life measures (Figure 3). Multiple linear regression, with
fortificant iron, haem iron and ‘natural’ (i.e. non-fortificant,
dietary-derived) non-haem iron as independent variables
(predictors) and the quality of life measure (i.e. EQ VAS,
EQ index or IBDQ score) as the dependent variable, also
showed no association. Furthermore, there were no statis-
tically significant differences for the intake of all ‘forms’ of
dietary iron between cases and controls in the matched
study group. A summary of the dietary intake of the main
nutrients in the matched cases and controls is presented
in Additional file 2: Table S1.
Although not part of the above main analysis we briefly
considered the six patients who relapsed during the study
period. Notably, these patients had significantly lower
dietary intakes of total and non-haem iron compared to
patients in remission (i.e. the cases in the matched study
group), even though total daily energy intakes and general
diet composition were comparable (Table 1). Unsurprisingly,
the relapsing patients also had lower quality of life scores
(Table 1) and, splitting the analysis into the four IBDQ
domains (i.e. bowel, systemic, emotional and social) showed
that, while all domains were associated with relapse of
disease, bowel and emotional function scores dropped
the most (Table 2). As observed previously [13] for the 6
patients who relapsed there was an inverse trend towards
lower IBDQ scores (i.e. quality of life) with higher total
dietary iron intakes (p = 0.029 for the comparison of the
Figure 3 Association between dietary iron intakes and quality of life measured with McMaster IBDQ for UC patients with quiescent
(closed triangles and full black line, n = 42) or relapsed (open triangles and dashed black line, n = 6) disease activity. A, total dietary iron;
B, haem iron; C, non-haem iron and D, fortificant iron. p = 0.029 (for total dietary iron, panel A) for the comparison of the slopes for the respective
linear associations using analysis of covariance (ANCOVA). For relapsing patients, further analysis was not considered appropriate for the sub-fractions
of dietary iron given the very small study numbers.
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slopes of the linear associations for active and inactive
disease, Figure 3). The significance of this difference
was further strengthened when the IBDQ scores were
adjusted for disease activity and total dietary iron was
expressed corrected for daily energy intakes (p = 0.0001,
Figure 4). Numbers were too small to consider subdividing
the analysis for the different forms of dietary iron.
Discussion
Our previous data have shown that elevated dietary iron
intakes, especially fortificant iron intakes, are associated
with a reduced quality of life in IBD patients with mild-
moderate disease activity [13]. This implies that during
relapse, luminal iron levels become an attributable factor
in the severity of inflammation. This is supported by
supplementation data in rodent models over the past
10 years as well as more recent work showing that
depletion of luminal iron alleviates gut inflammation
in IBD models [6,7,28].
The aim of the present study was to investigate if, in
the absence of inflammation (i.e. in inactive (quiescent)
disease), this might still be the case. Our results show that,
in the absence of clinical disease activity (i.e. SCCAI < 5),
there was no measurable linear association between
dietary iron intakes and quality of life which is consistent
with earlier preliminary findings [13].
However, even though the numbers are very small
(n = 6), our data in UC patients that relapsed after enrolling
in the study, and developed mild-moderate active disease,
again showed a negative association between dietary iron
intake and the disease-specific quality of life score (IBDQ).
This very small number of patients would not justify
further sub-analysis but we do note that, for all UC patients
studied herein, the IBDQ scores gave a good correlation
Figure 4 Association between dietary iron intakes and adjusted
IBDQ scores for UC patients with quiescent (closed
triangles and full black line, n = 42) and relapsed (open
triangles and dashed black line, n = 6) disease activity.
IBDQ scores are predicted values adjusted for age and gender
(entered as covariates in the linear regression model). Dietary iron is
expressed as iron density values. p = 0.0001 for the comparison of
the slopes for the respective linear associations using analysis of
covariance (ANCOVA).
Table 2 Individual scores of the IBDQ domains
Patients in
remission (n = 42)
Patients in
relapse (n = 6)
Mean (95% CI) Mean (95% CI) p-value*
IBDQ Bowel
(10 questions)
62 (60–64) 41 (29–54) <0.0001
IBDQ Systemic
(5 questions)
28 (26–30) 23 (15–30) ns
IBDQ Emotional
(12 questions)
72 (70–75) 49 (35–64) <0.0001
IBDQ Social
(5 questions)
34 (33–35) 27 (18–35) 0.0004
Abbreviations: IBDQ McMaster inflammatory bowel disease questionnaire, CI
confidence interval. *Mann–Whitney nonparametric test. Statistical significance
was considered at p < 0.05. ns, not significant.
Table 1 Simple Colitis Clinical Activity Index score,
quality of life scores and dietary intakes of main
nutrients in UC patients in remission or relapse
Patients in
remission (n = 42)
Patients in
relapse (n = 6)
Mean (95% CI) Mean (95% CI) p-value*
Age 51 (46–55) 44 (35–52) ns
SCCAI (score/19) 2.3 (1.9-2.7) 7.3 (5.3-9.4) <0.0001
EQ VAS (%) 82 (79–86) 58 (36–79) 0.002
EQ index value 0.90 (0.86-0.93) 0.76 (0.63-0.89) 0.005
IBDQ (score 32–224) 196 (190–202) 140 (98–181) <0.0001
Energy intake (MJ/d) 8.71 (8.11-9.31) 8.13 (6.60-9.67) ns
Carbohydrates (g/d) 246 (226–265) 247 (198–297) ns
Protein (g/d) 82.0 (75.5-88.4) 67.0 (47.9-86.0) ns
Fat (g/d) 77.7 (71.4-83.9) 80.9 (61.9-99.9) ns
Fibre (g/d) 15.6 (14.0-17.2) 12.9 (10.8-15.1) ns
Zing (mg/d) 11.4 (10.2-12.6) 11.1 (5.0-17.2) ns
Calcium (mg/d) 1,059 (949–1,168) 1,003 (738–1,269) ns
Total Fe (mg/d) 13.1 (12.0-14.2) 9.6 (7.9-11.3) 0.006
Haem Fe (mg/d) 0.73 (0.54-0.92) 0.41 (0.18-0.64) ns
Non-haem Fe (mg/d) 8.5 (7.7-9.4) 5.9 (4.7-7.2) 0.007
Fortificant Fe (mg/d) 3.5 (2.7-4.3) 3.2 (1.8-4.7) ns
Abbreviations: SCCAI simple colitis clinical activity index, EQ EuroQol
EQ-5D-5 L, EQ VAS EuroQuol Visual Analogue Scale score, IBDQ McMaster
inflammatory bowel disease questionnaire, MJ megajoules (equals 1000
kilojoules), Fe iron, CI confidence interval. *Mann–Whitney nonparametric
test. Statistical significance was considered at p < 0.05. ns, not
significant.
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with EuroQol scores, especially EQ VAS(%) (Additional
file 3: Figure S2). The small dataset also showed that mean
dietary iron intakes were lower in the UC patients with
mild-moderate active disease compared with their counter-
parts in remission and this is in agreement with previous
studies in IBD [29]. It suggests that the disease state, itself,
modifies patient food choice.
The use of 7-day food diet diaries and carefully matched
control data means that we can suggest confidently, from
this work that dietary iron does not have any clinically
meaningful effect on quality of life in UC patients with
inactive disease. However, the picture appears different
in the presence of existing mucosal inflammation: some
degree of disease activity, even if mild (SCCAI ≥ 5), may
be sufficient to allow a detectable association between
quality of life and dietary iron intake (Figure 3A and [13]).
Moreover, this appears to be driven by fortificant iron [13].
Taken together, there may also be important resonances
between our studies (here and [13]) and the recent work of
Radulescu et al. [9] where dietary iron was shown to be a
permissive factor for colon cancer development in murine
models.
Conclusions
We propose that luminal free iron may be a contributing
factor in the severity of colonic inflammation, once
triggered through another means, in patients with UC. We
do acknowledge that data from the robust observational
study presented here only provide suggestion of associa-
tions and a more conclusive intervention study in patients
with active disease is now required. If the association
shown here and in our prior preliminary work [13] is
confirmed, then, whether it operates through the well
described reactive oxygen species-inducing nature of
reactive iron in the colon, or through iron’s modulation of
the microbiota [7], or indeed some other mechanisms(s)
would warrant careful investigation, as would the possibility
of intervention through sequestration of free luminal iron
in the distal bowel.
Additional files
Additional file 1: Figure S1. Association between dietary iron intakes
and quality of life measured with EuroQol index in UC patients with
quiescent disease (closed triangles and full black line) and matched
‘healthy’ controls (open circles and dashed black line). A, total dietary
iron; B, haem iron; C, non-haem iron; D, fortificant iron. There were no
significant slope deviations from zero (linear regression) for both UC
patients and matched controls (p>0.05, n=34 per group).
Additional file 2: Table S1. Age, quality of life and dietary intakes of
main nutrients in matched cases and controls.
Additional file 3: Figure S2. Linear association between quality of life
measured with the McMaster IBDQ and the generic EuroQol EQ-5D-5L. A,
EQ VAS, EuroQuol Visual Analogue Scale score; B, EQ index value. The
best-fit line is shown with the 95% confidence band and the p-value for
the linear associations: n=48.
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